Evidence map›Paper›PMID 34728170›Full record

ArticleAnales de pediatria2021

COVID-19 pandemic. What have we learned?

Cristina Calvo, Alfredo Tagarro, Ana Méndez Echevarría, Belén Fernández Colomer, M Rosa Albañil Ballesteros, Quique Bassat, M José Mellado Peña

Abstract read
In one paragraph

Article in Anales de pediatria, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. COVID in Pediatric Age: an opinion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cristina CalvoServicio de Pediatría, Enfermedades Infecciosas y Tropicales, Hospital Universitario La Paz, Madrid, Spain; Red de Investigación traslacional en infectología Pediátrica (RITIP), Spain. Electronic address: ccalvor@salud.madrid.org.
Alfredo TagarroRed de Investigación traslacional en infectología Pediátrica (RITIP), Spain; Unidad de Pediatría Investigación y Ensayos Clínicos (UPIC), Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid; Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Madrid; Servicio de Pediatría, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Madrid, Spain.
Ana Méndez EchevarríaServicio de Pediatría, Enfermedades Infecciosas y Tropicales, Hospital Universitario La Paz, Madrid, Spain; Red de Investigación traslacional en infectología Pediátrica (RITIP), Spain.
Belén Fernández ColomerComisión de Infección, Sociedad Española de Neonatología (SENeo), Spain.
M Rosa Albañil BallesterosCentro de Salud Cuzco, Fuenlabrada, Madrid; Grupo de Patología Infecciosa de la Asociación Española de Pediatría de Atención Primaria (AEPap), Spain.
Quique BassatISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique; ICREA, Barcelona, Spain; Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues de Llobregat, Barcelona, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
M José Mellado PeñaServicio de Pediatría, Enfermedades Infecciosas y Tropicales, Hospital Universitario La Paz, Madrid, Spain; Red de Investigación traslacional en infectología Pediátrica (RITIP), Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the COVID-19 pandemic was declared in March 2020, we have learned a lot about the SARS-CoV-2 coronavirus, and its role in pediatric pathology. Children are infected in a rate quite similar to adults, although in most cases they suffer mild or asymptomatic symptoms. Around 1% of those infected require hospitalization, less than 0.02% require intensive care, and mortality is very low and generally in children with comorbidities. The most common clinical diagnoses are upper or lower respiratory infections, gastrointestinal infection and, more seriously, multisystemic inflammatory syndrome (MIS-C). Most episodes do not require treatment, except for MIS-C. Remdesivir has been widely used as a compassionate treatment and its role has yet to be defined. The newborn can become infected, although vertical transmission is very low (<1%) and it has been shown that the baby can safely cohabit with its mother and be breastfed. In general, neonatal infections have been mild. Primary care has supported a very important part of the management of the pandemic in pediatrics. There has been numerous collateral damage derived from the difficulty of access to care and the isolation suffered by children. The mental health of the pediatric population has been seriously affected. Although it has been shown that schooling has not led to an increase in infections, but rather the opposite. It is essential to continue maintaining the security measures that make schools a safe place, so necessary not only for children's education, but for their health in general.

Indexed as

COVID-19PandemicsAdultChildFemaleHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalSARS-CoV-2Systemic Inflammatory Response SyndromeColegiosCOVID-19NeonatesNeonatosSARS-CoV-2Schools

Identifiers

PMID34728170
PMCPMC8529266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.